1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Humanigen, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 Lenzilumab, Standard of Care - Coronavirus Disease 2019 (COVID-19) Pneumonia | Phase 3 | Unknown | Humanigen, Inc. | 520 | 2020-05-05 | 2021-03-03 |
COVID-19 (1) · Cytokine Release Syndrome (1) · Pneumonia (1)
Standard of Care (1) · lenzilumab (1)
Brazil (1) · United States (1)
PMID 33153629, PMID 33673929, PMID 33972949, PMID 34863332, PMID 35793833